Visualising microglial activation in vivo
- PMID: 12379908
- DOI: 10.1002/glia.10144
Visualising microglial activation in vivo
Abstract
In health, microglia reside as quiescent guardian cells ubiquitously, but isolated without any cell-cell contacts amongst themselves, throughout the normal CNS. In disease, however, they act as swift "sensors" for pathological events, including subtle ones without any obvious structural damage. Once activated, microglia show a territorially highly restricted involvement in the disease process. This property, peculiar to microglia, confers to them diagnostic value for the accurate spatial localisation of any active disease process, acute or chronic. In the brain, the isoquinoline PK11195, a ligand for the peripheral benzodiazepine binding site (PBBS), binds with relative cellular selectivity to activated, but not resting, microglia. Labelled with carbon-11, (R)-PK11195 and positron emission tomography (PET) have been used for the study of inflammatory and neurodegenerative brain disease in vivo. These studies demonstrate meaningfully distributed patterns of regional [(11)C](R)-PK11195 signal increases that correlate with clinically observed loss of function. Increased [(11)C](R)-PK11195 binding closely mirrors the histologically well-described activation of microglia in the penumbra of focal lesions, as well as in the distant, anterograde, and retrograde projection areas of the lesioned neural pathway. There is also some indication that in long-standing alterations of a neural network with persistent abnormal input, additional signals of glial activation may also emerge in transsynaptic areas. These data suggest that the injured brain is less static than commonly thought and shows subtle glial responses even in macroanatomically stable appearing regions. This implies that glial activation is not solely a sign of tissue destruction, but possibly of disease-induced adaptation or plasticity as well. Whilst further technological and methodological advances are necessary to achieve routine clinical value and feasibility, a systematic attempt to image glial cells in vivo is likely to furnish valuable information on the cellular pathology of CNS diseases and their progression within the distributed neural architecture of the brain.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.Brain. 2000 Nov;123 ( Pt 11):2321-37. doi: 10.1093/brain/123.11.2321. Brain. 2000. PMID: 11050032
-
In vivo imaging of neuroinflammation.Eur Neuropsychopharmacol. 2002 Dec;12(6):581-6. doi: 10.1016/s0924-977x(02)00107-4. Eur Neuropsychopharmacol. 2002. PMID: 12468021 Review.
-
Positron emission tomography imaging of neuroinflammation.Neurotherapeutics. 2007 Jul;4(3):443-52. doi: 10.1016/j.nurt.2007.04.006. Neurotherapeutics. 2007. PMID: 17599710 Free PMC article. Review.
-
PK ('peripheral benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia.J Neurocytol. 1997 Feb;26(2):77-82. doi: 10.1023/a:1018567510105. J Neurocytol. 1997. PMID: 9181482
-
Mitochondria in activated microglia in vitro.J Neurocytol. 2004 Sep;33(5):535-41. doi: 10.1007/s11068-004-0515-7. J Neurocytol. 2004. PMID: 15906160
Cited by
-
Association of Neurofilament Light Chain, [18F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid-Negative CBS.Neurology. 2024 Jan 9;102(1):e207901. doi: 10.1212/WNL.0000000000207901. Epub 2023 Dec 14. Neurology. 2024. PMID: 38165362
-
Integrating TSPO PET imaging and transcriptomics to unveil the role of neuroinflammation and amyloid-β deposition in Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):455-467. doi: 10.1007/s00259-023-06446-3. Epub 2023 Oct 6. Eur J Nucl Med Mol Imaging. 2024. PMID: 37801139 Free PMC article.
-
Concussion: Beyond the Cascade.Cells. 2023 Aug 22;12(17):2128. doi: 10.3390/cells12172128. Cells. 2023. PMID: 37681861 Free PMC article. Review.
-
Theoretical design for covering Engeletin with functionalized nanostructure-lipid carriers as neuroprotective agents against Huntington's disease via the nasal-brain route.Front Pharmacol. 2023 Jul 10;14:1218625. doi: 10.3389/fphar.2023.1218625. eCollection 2023. Front Pharmacol. 2023. PMID: 37492081 Free PMC article.
-
Lactoferrin alleviates Western diet-induced cognitive impairment through the microbiome-gut-brain axis.Curr Res Food Sci. 2023 Jun 15;7:100533. doi: 10.1016/j.crfs.2023.100533. eCollection 2023. Curr Res Food Sci. 2023. PMID: 37351541 Free PMC article.
References
REFERENCES
-
- Alho H, Varga V, Krueger KE. 1994. Expression of mitochondrial benzodiazepine receptor and its putative endogenous ligand diazepam binding inhibitor in cultured primary astrocytes and C-6 cells: relation to cell growth. Cell Growth Differ 9: 1005-1014.
-
- Anholt RR, Pedersen PL, DeSouza EB, Snyder SH. 1986. The peripheral-type benzodiazepine receptor. Localisation to the mitochondrial outer membrane. J Biol Chem 261: 776-783.
-
- Banati RB, Graeber MB. 1994. Surveillance, intervention and cytotoxicity: is there a protective role of microglia? Dev Neurosci 16: 114-127.
-
- Banati RB, Gehrman J, Schubert P, Kreutzberg GW. 1993. Cytotoxicity of microglia. Glia 7: 111-118.
-
- Banati RB, Myers R, Kreutzberg GW. 1997. PK (“peripheral benzodiazepine”)-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H] PK11195 binding to activated microglia. J Neurocytol 26: 77-82.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
